Aurobindo Pharma Limited (AUROPHARMA)

Price866.40 -10.05 (-1.15%)52 Week High907.70
ISININE406A0103752 Week Low397.20
IndustryPharmaceuticals: OtherVolume1.4 M
SectorHealth TechnologyP/E Ratio TTM25.67
Market Cap513.3 B1 Year Beta0.66
Technical Rating of

Aurobindo Pharma Limited (AUROPHARMA) logo
  • Aurobindo Pharma Limited (AUROPHARMA) is an Indian multinational pharmaceutical company headquartered in Hyderabad, India. It was founded in 1986 by P. V. Ramana Rao.
  • Aurobindo’s initial focus was on the manufacturing of generic pharmaceuticals. It has since expanded its operations to include a wide range of products, including APIs, finished dosages, and biosimilars.
  • Aurobindo is one of the leading pharmaceutical companies in India. The company has a pan-India presence and exports its products to over 150 countries.
  • Aurobindo is a publicly traded company, listed on the Bombay Stock Exchange and the National Stock Exchange of India. The company has a market capitalization of over ₹50,000 crore (US$6.25 billion).
  • Aurobindo is well-positioned for continued growth in the future. The company is targeting to expand its product portfolio and increase its market share.

Here are some of the key points about Aurobindo Pharma Limited:

  • Founded in 1986
  • Headquartered in Hyderabad, India
  • One of the leading pharmaceutical companies in India
  • Pan-India presence and exports to over 150 countries
  • Publicly traded company
  • Market capitalization of over ₹50,000 crore (US$6.25 billion)
  • Well-positioned for continued growth in the future
  • The company has a strong focus on innovation. It was the first Indian pharmaceutical company to launch a biosimilar product.
  • Aurobindo is also a major supplier of pharmaceutical products to the government and the private healthcare sectors.
          

Aurobindo Pharma Limited (AUROPHARMA) Chart

Technical Analysis of Aurobindo Pharma Limited (AUROPHARMA)

Moving Averages

PeriodSimpleExponential
MA 5885.26879.16
MA 10882.20877.24
MA 20859.75866.87
MA 30859.00855.32
MA 50836.32827.99
MA 100749.51759.94
MA 200612.34681.20

Moving Average Rating

Technical Indicators

NameValueNameValue
Aroon Up (14)57.14Aroon Down (14)7.14
MACD Level (12, 26)15.11MACD Signal (12, 26)15.87
Relative Strength Index (7)42.65Relative Strength Index (14)53.31
Stochastic %D (14 3 3)76.79Stochastic %K (14 3 3)67.27
Stochastic RSI Fast (3, 3, 14, 14)46.17Stochastic RSI Slow (3, 3, 14, 14)63.22
Bollinger Upper Band (20)913.69Bollinger Lower Band (20)805.80
Keltner Channels Upper Band (20)910.05Keltner Channels Lower Band (20)823.69
Donchian Channels Upper Band (20)907.70Donchian Channels Lower Band (20)815.80
Ichimoku Conversion Line (9, 26, 52, 26)876.43Ichimoku Base Line (9, 26, 52, 26)861.75
Ichimoku Leading Span A (9, 26, 52, 26)831.99Ichimoku Leading Span B (9, 26, 52, 26)770.38
Positive Directional Indicator (14)19.81Negative Directional Indicator (14)23.07
Volume Weighted Average Price862.53Volume Weighted Moving Average 20864.63

Oscillator Rating

Oscillators

Awesome Oscillator27.06
Ultimate Oscillator (7,14,28)54.23
Money Flow (14)70.32
Chaikin Money Flow (20)0.07
Commodity Channel Index (20)9.08
Bull Bear Power-27.25

High / Low

1 Month907.70815.80
3 Month907.70696.60
6 Month907.70498.35
52 Week907.70397.20
All Time1,063.906.80

Volume

Volume1.4 M
Average 10 D1.9 M
Average 30 D1.8 M
Average 60 D2 M
Average 90 D2 M

Change/Volatility

Change-10.05 (-1.15%)
Change 1W-32.45 (-3.61%)
Change 1M36.40 (4.39%)
Volatility3.70
Volatility W2.48

Performance

Yesterday96.95
Weekly-3.60
Monthly2.72
3 Month29.70
6 Month78.27
Yearly65.00
5 Year13.11
All Time9,266.49

Misc.

Average Day Range (14)21.80
Average Directional Index (14)28.12
Average True Range (14)21.43
Williams Percent Range (14)-44.94
Rate Of Change (9)0.92
Hull Moving Average (9)879.35
Momentum (10)4.70
Parabolic SAR907.70

PIVOT POINTS of Aurobindo Pharma Limited (AUROPHARMA)

NameS3S2S1Pivot PointsR1R2R3
Classic677.02759.07794.53841.12876.58923.171,005.22
Fibonacci759.07790.41809.77841.12872.46891.82923.17
Camarilla807.44814.96822.48841.12837.52845.04852.56
Woodie's706.93756.29788.98838.34871.02920.39953.07
DeMark's - - 817.83852.76899.88 - -

Financial Analysis of Aurobindo Pharma Limited (AUROPHARMA)

Income Statement

Basic EPS (FY)32.90
Basic EPS (TTM)33.75
EBITDA (Annual YoY Growth)-14.28
EBITDA (Quarterly QoQ Growth)14.89
EBITDA (Quarterly YoY Growth)19.35
EBITDA (TTM)39.4 B
EBITDA (TTM YoY Growth)-4.76
EPS Diluted (Annual YoY Growth)-27.21
EPS Diluted (FY)32.90
EPS Diluted (MRQ)9.74
EPS Diluted (Quarterly QoQ Growth)12.74
EPS Diluted (Quarterly YoY Growth)9.65
EPS Diluted (TTM)33.75
EPS Diluted (TTM YoY Growth)-17.55
EPS Forecast (MRQ)11.60
Free Cash Flow (Annual YoY Growth)-99.21
Free Cash Flow Margin (FY)0.07
Gross Profit (Annual YoY Growth)-1.37
Gross Profit (FY)69 B
Gross Profit (MRQ)24.2 B
Gross Profit (Quarterly QoQ Growth)3.10
Gross Profit (Quarterly YoY Growth)10.40
Gross Profit (TTM YoY Growth)3.22
Last Year Revenue (FY)246.4 B
Revenue (Annual YoY Growth)5.18
Revenue per Employee (FY)7.4 M
Revenue (Quarterly QoQ Growth)5.83
Revenue (Quarterly YoY Growth)9.86
Revenue (TTM YoY Growth)6.17
Net Income (Annual YoY Growth)-27.21
Net Income (FY)19.3 B
Net Income (Quarterly QoQ Growth)12.74
Net Income (Quarterly YoY Growth)9.65
Net Income (TTM YoY Growth)-17.55
Total Revenue (FY)246.4 B

Valuation

Enterprise Value/EBITDA (TTM)13.01
Number of Employees33,413.00
Number of Shareholders343.6 T
Shares Float281.6 M
Price to Book (FY)1.89
Price to Earnings Ratio (TTM)25.67
Price to Revenue Ratio (TTM)1.99
Price to Sales (FY)2.06
Total Shares Outstanding585.9 M
Research & development Ratio (FY)5.73
Research & development Ratio (TTM)5.85
Selling & Admin expenses Ratio (FY)11.41
Selling & Admin expenses Ratio (TTM)19.16

Balance Sheet

Total Assets (Annual YoY Growth)17.59
Total Debt (Annual YoY Growth)61.22
Total Liabilities (FY)130.4 B
Cash & Equivalents (FY)44 B
Cash and short term investments (FY)62.4 B

Operating Metrics

Dividends

Dividend Yield Forward1.03
Dividends Paid (FY)-4,395,300,000.00

Margins

Net Margin (FY)7.82
Net Margin (TTM)7.76
Gross Margin (FY)28.01
Gross Margin (TTM)35.43
Operating Margin (FY)10.45
Operating Margin (TTM)10.42
Pretax Margin (TTM)10.82

Aurobindo Pharma Limited (AUROPHARMA) FUTURES

ExpiryOpenHighLowCloseSettleContractsValueOIOI Change
28-Sep-23877.85878.20847.10868.75868.755.3 T50.6 T11.4 M-2,337,500
26-Oct-23883.80884.00852.80874.45874.453.1 T30 T3 M2.4 M
30-Nov-23884.00885.55860.00879.45879.455250158.3 T-5,500

Aurobindo Pharma Limited (AUROPHARMA) OPTIONS

Related Companies (Peers) to Aurobindo Pharma Limited (AUROPHARMA)

Price635.95 2.00 (0.32%)52 Week High775.45
ISININE098F0103152 Week Low554.05
IndustryPharmaceuticals: OtherVolume32,284
SectorHealth TechnologyP/E Ratio TTM43.12
Market Cap18.5 B1 Year Beta0.88
Technical Rating of
Amrutanjan Health Care Limited (AMRUTANJAN) is an Indian pharmaceutical company headquartered in Hyderabad, India. It was incorporated in 1965. The company’s initial focus was on the manufacturing of pain relief balms. Amrutanjan has since expanded its operations to include a wide range of over-the-counter (OTC) products, including cough syrups, cold remedies, and skin care products. more about Amrutanjan Health Care Limited (AMRUTANJAN)

Price1,185.90 -20.50 (-1.70%)52 Week High1,277.90
ISININE059A0102652 Week Low852.00
IndustryPharmaceuticals: OtherVolume2.8 M
SectorHealth TechnologyP/E Ratio TTM30.77
Market Cap974.5 B1 Year Beta0.06
Technical Rating of
Cipla Limited (CIPLA) is an Indian multinational pharmaceutical company headquartered in Mumbai, India. It was founded in 1935 by Khwaja Abdul Hamied. CIPLA is one of the largest pharmaceutical companies in India and has a global presence, with operations in over 150 countries. The company’s products include generic drugs, branded drugs, and over-the-counter (OTC) products. more about Cipla Limited (CIPLA)

Price336.80 13.60 (4.21%)52 Week High381.00
ISININE101D0102052 Week Low267.75
IndustryPharmaceuticals: OtherVolume3.8 M
SectorHealth TechnologyP/E Ratio TTM18.89
Market Cap78.2 B1 Year Beta0.79
Technical Rating of
Granules India Limited (GRANULES) is a well-established company with a strong track record in the Indian pharmaceutical industry. The company is a leading manufacturer of active pharmaceutical ingredients (APIs) and finished dosages in India. GRANULES has a strong customer base in the Indian and global pharmaceutical markets. GRANULES is well-positioned to capitalize on the growing more about Granules India Limited (GRANULES)

Price1,097.45 -29.85 (-2.65%)52 Week High1,174.50
ISININE326A0103752 Week Low628.00
IndustryPharmaceuticals: OtherVolume1.3 M
SectorHealth TechnologyP/E Ratio TTM51.59
Market Cap513.9 B1 Year Beta0.46
Technical Rating of
Lupin Limited (LUPIN) is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. It was founded in 1968 by Mr. Desh Bandhu Gupta. LUPIN is one of the largest pharmaceutical companies in India, with a market capitalization of over $20 billion. The company manufactures a wide range of generic and branded pharmaceutical products, including anti-infectives, more about Lupin Limited (LUPIN)

Price113.05 2.55 (2.31%)52 Week High155.90
ISININE933A0101452 Week Low88.50
IndustryPharmaceuticals: OtherVolume91,139
SectorHealth TechnologyP/E Ratio TTM
Market Cap3.7 B1 Year Beta0.96
Technical Rating of
Lyka Labs Limited (LYKALABS) is an Indian pharmaceutical company headquartered in Ahmedabad, Gujarat. It was founded in 1990 by Mr. Rajesh Shah. LYKALABS is a leading manufacturer of generic APIs (active pharmaceutical ingredients) and finished dosage forms. The company’s products are used in a wide range of therapeutic areas, including anti-infectives, anti-diabetics, and cardiovascular drugs. more about Lyka Labs Limited (LYKALABS)

Aurobindo Pharma Limited (AUROPHARMA) Related Indices

The Nifty 200 Index is designed to reflect the behaviour and performance of large and mid market capitalization companies . Nifty 200 includes all companies forming part of Nifty 100 and Nifty Full Midcap 100 index. The Nifty 200 Index represents about 86% of the free float market capitalization of the stocks listed on NSE as on March 31, 2016. The total traded value for the last six months ending March 2016, of all index constituents is approximately 77% of the traded value of all stocks on NSE. more about Nifty 200

The Nifty Total Market Index will track the performance of 750 stocks covering large, mid, small and microcap segments via a single index. All stocks that are part of Nifty 500 index and Nifty Microcap 250 index form part of the Nifty Total Market index. Stock’s weight is based on its free-float market capitalization. more about Nifty Total Market

The Nifty 500 represents the top 500 companies based on full market capitalisation and average daily turnover from the eligible universe. It represents about 94% of the free float market capitalization of the stocks listed on NSE as on March 31, 2016. The total traded value for the last six months ending March 2016, of all Index constituents is approximately 87% of the traded value of all stocks on NSE. more about Nifty 500

The Nifty500 Multicap 50:25:25 index aims to measure the performance of portfolio of large, mid and small market capitalisation companies with target weights assigned to each size segment. The Nifty500 Multicap 50:25:25 index includes all companies that are part of Nifty 500 index. While in Nifty 500 index, the total weight of each size segment (Large, Mid and Small cap) is based on the total free float market capitalisation of all stocks falling within that size segment, in Nifty500 Multicap 50:25:25 index, the total weight of each of these three segments (Large, Mid and Small cap) is fixed at 50%, 25% and 25% respectively at every quarterly rebalance date. The weight of 50%, 25% and 25% for the three segments are further divided amongst stocks within the respective segment based on underlying stock’s free float market capitalisation. Weight of each size segment may be different from its respective capped level between two rebalance dates due to price drift of underlying stocks. more about Nifty500 Multicap 50:25:25

Nifty Midcap 150 represents 150 companies (companies ranked 101-250) based on full market capitalisation from Nifty 500. The Nifty Midcap 150 Index represents about 11.4% of the free float market capitalization of the stocks listed on NSE as on March 31, 2016. The total traded value for the last six months ending March 2016, of all index constituents is approximately 19% of the traded value of all stocks on NSE. more about Nifty Midcap150

Nifty Midcap 50 index represent top 50 companies based on full market capitalisation from Nifty Midcap 150 index and on which derivative contracts are available on National Stock Exchange (NSE). more about Nifty Midcap 50

Nifty Midcap Select index aims to track the performance of focused portfolio of 25 stocks within the Nifty Midcap 150 index. The stocks are selected based on market cap, average daily turnover and availability for trading on NSE’s Futures & Options segment (F&O) are eligible to be the part of the index. The weight of the stocks is based on free-float market capitalization more about Nifty Midcap Select

The Nifty Midcap 100 Index captures the movement of the midcap segment of the market. The Nifty Midcap 100 Index comprises 100 tradable stocks listed on the National Stock Exchange (NSE). The Nifty Midcap 100 Index represents about 11% of the free float market capitalization of the stocks listed on NSE as on March 31, 2018. The total traded value for the last six months ending March 2018, of all index constituents is approximately 20% of the traded value of all stocks on NSE. more about Nifty Midcap 100

The Nifty LargeMidcap 250 reflects the performance of a portfolio of 100 large cap and 150 mid cap companies listed on NSE, represented through the Nifty 100 and the Nifty Midcap 150 index respectively. The aggregate weight of large cap stocks and mid cap stocks is 50% each and are reset on a quarterly basis. The index has a base date of April 01, 2005 and a base value of 1000. The Index is reconstituted on a semi-annual basis along with Nifty 100 and Nifty Midcap 150 index. more about Nifty LargeMidcap 250

The Nifty MidSmallcap 400 Index is designed to reflect the behaviour and performance of the mid and small market capitalisation companies. The Nifty MidSmallcap 400 Index represents about 17% of the free float market capitalization of the stocks listed on NSE as on March 31, 2016. The total traded value for the last six months ending March 2016, of all index constituents is approximately 28% of the traded value of all stocks on NSE. more about Nifty MidSmallcap 400

The Nifty Healthcare Index is designed to reflect the behaviour and performance of the Healthcare companies. The Nifty Healthcare Index comprises of maximum of 20 stocks that are listed on the National Stock Exchange. more about Nifty Healthcare

The Nifty Pharma Index is designed to reflect the behavior and performance of the pharmaceutical sector in India. more about Nifty Pharma

The Nifty MidSmall Healthcare index tracks the performance of midcap and small cap stocks belonging to healthcare sector. Index includes upto 30 stocks. Stock weights are based on free-float market capitalization. more about Nifty MidSmall Healthcare

Nifty Midcap Liquid 15 Index is designed to provide investors exposure to the liquid midcap stocks while making the index easily replicable and tradable. more about Nifty Midcap Liquid 15

The Nifty200 Momentum 30 Index aims to track the performance of 30 high momentum stocks across large and mid-cap stocks. The Momentum Score for each stock is based on recent 6-month and 12-month price return, adjusted for volatility. more about Nifty200 Momentum 30

Nifty Midcap150 Momentum 50 Index aims to track the performance of the top 50 companies within the Nifty Midcap 150 selected based on their Normalized Momentum Score. The Normalized Momentum Score for each company is determined based on its 6-month and 12-month price return, adjusted for volatility. Stock weights are based on a combination of the stock’s Normalized Momentum Score and its free-float market capitalization. more about Nifty Midcap150 Momentum 50

News Related to Aurobindo Pharma Limited (AUROPHARMA)

  1. Sep 22, 2023, 4:46 pm

    Pharma Sector Sees Bearish Sentiment on September 22 The pharmaceutical sector is experiencing bearish sentiment on September 22, with profit-booking pressure and short positions in several individual stocks, including Glenmark, Cipla, Alkem, and Dr Reddy's. Analysts believe that the Nifty Pharma Index could see further weakness if it breaks below the 14700-14800 support zone. On the other hand, Aurobindo Pharma is seen as a moderately bullish stock, with strong resistance at the 900 strike price and strong support at the 850 and 860 strike prices. Traders should be cautious and monitor the market closely for any further developments.

More News >>

Leave a Reply

Your email address will not be published. Required fields are marked *

Stock Sectors
Stock Industries